S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia

Intra-Cellular Therapies (ITCI) Competitors

$65.82
+0.54 (+0.83%)
(As of 06/9/2023 ET)
Compare
Today's Range
$64.70
$65.93
50-Day Range
$54.67
$66.44
52-Week Range
$42.01
$66.56
Volume
475,965 shs
Average Volume
616,371 shs
Market Capitalization
$6.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.82

ITCI vs. IONS, GRFS, CTLT, ISEE, ASND, CERE, ROIV, OGN, ALKS, and MDGL

Should you be buying Intra-Cellular Therapies stock or one of its competitors? The main competitors of Intra-Cellular Therapies include Ionis Pharmaceuticals (IONS), Grifols (GRFS), Catalent (CTLT), IVERIC bio (ISEE), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Roivant Sciences (ROIV), Organon & Co. (OGN), Alkermes (ALKS), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "pharmaceutical preparations" industry.

Intra-Cellular Therapies vs.

Ionis Pharmaceuticals (NASDAQ:IONS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Ionis Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Intra-Cellular Therapies has lower revenue, but higher earnings than Ionis Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$587 million9.91-$269.72 million-$2.31-17.60
Intra-Cellular Therapies$250.31 million25.23-$256.26 million-$2.40-27.42

Ionis Pharmaceuticals has a net margin of -56.85% compared to Intra-Cellular Therapies' net margin of -73.46%. Intra-Cellular Therapies' return on equity of -33.92% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals -56.85% -57.58% -12.74%
Intra-Cellular Therapies -73.46% -33.92% -29.72%

Ionis Pharmaceuticals received 182 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. However, 66.81% of users gave Intra-Cellular Therapies an outperform vote while only 60.39% of users gave Ionis Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Ionis PharmaceuticalsOutperform Votes
657
60.39%
Underperform Votes
431
39.61%
Intra-Cellular TherapiesOutperform Votes
475
66.81%
Underperform Votes
236
33.19%

In the previous week, Intra-Cellular Therapies had 2 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 11 mentions for Intra-Cellular Therapies and 9 mentions for Ionis Pharmaceuticals. Intra-Cellular Therapies' average media sentiment score of 0.67 beat Ionis Pharmaceuticals' score of 0.60 indicating that Intra-Cellular Therapies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ionis Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Intra-Cellular Therapies
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

87.3% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 87.0% of Intra-Cellular Therapies shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 3.4% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ionis Pharmaceuticals currently has a consensus price target of $46.64, indicating a potential upside of 14.73%. Intra-Cellular Therapies has a consensus price target of $74.82, indicating a potential upside of 13.67%. Given Ionis Pharmaceuticals' higher probable upside, equities research analysts clearly believe Ionis Pharmaceuticals is more favorable than Intra-Cellular Therapies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals
1 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.40
Intra-Cellular Therapies
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

Summary

Intra-Cellular Therapies beats Ionis Pharmaceuticals on 10 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ITCI vs. The Competition

MetricIntra-Cellular TherapiesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.31B$5.58B$4.58B$6.28B
Dividend YieldN/A2.60%2.26%6.27%
P/E Ratio-27.425.2092.9512.78
Price / Sales25.23331.903,376.9090.51
Price / CashN/A20.8894.08115.16
Price / Book9.504.684.715.30
Net Income-$256.26M$183.75M$117.47M$193.31M
7 Day Performance7.34%0.33%0.81%1.29%
1 Month Performance-0.93%0.04%1.01%4.61%
1 Year Performance24.14%21.20%19.11%5.86%

Intra-Cellular Therapies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IONS
Ionis Pharmaceuticals
1.6332 of 5 stars
$43.33
+2.5%
$46.64
+7.6%
+16.4%$6.20B$587M-18.76660
GRFS
Grifols
2.1709 of 5 stars
$8.85
+1.6%
$12.52
+41.5%
-29.9%$6.08B$6.39B0.0026,314Gap Up
CTLT
Catalent
3.1125 of 5 stars
$38.82
+2.7%
$67.55
+74.0%
-64.7%$6.99B$4.83B17.1819,000
ISEE
IVERIC bio
1.3425 of 5 stars
$38.90
+0.5%
$27.45
-29.4%
+258.9%$5.36BN/A-22.1094Insider Selling
ASND
Ascendis Pharma A/S
2.1167 of 5 stars
$92.22
+0.4%
$148.09
+60.6%
+6.9%$5.29B$53.93M-8.79639
CERE
Cerevel Therapeutics
1.2492 of 5 stars
$33.05
+0.8%
$34.80
+5.3%
+17.2%$5.18BN/A-13.06200
ROIV
Roivant Sciences
1.7447 of 5 stars
$9.75
+3.5%
$12.80
+31.3%
+150.1%$7.39B$55.29M-5.48620Analyst Report
Insider Selling
News Coverage
Positive News
OGN
Organon & Co.
3.0641 of 5 stars
$20.08
-0.6%
$29.00
+44.5%
-45.5%$5.12B$6.17B6.8810,000
ALKS
Alkermes
1.9552 of 5 stars
$30.40
+3.2%
$31.67
+4.2%
+10.7%$5.05B$1.12B-30.712,280Analyst Report
News Coverage
MDGL
Madrigal Pharmaceuticals
2.3105 of 5 stars
$273.83
+2.7%
$312.36
+14.1%
+247.2%$5.01BN/A-15.1371

Related Companies and Tools

This page (NASDAQ:ITCI) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -